Showing: 1 - 10 of 105 RESULTS
Briefing News Psyched Wellness Psychedelics

Psyched Wellness Sees Amanita Muscaria Approved As Medicinal Organism By Health Canada

After more than a years worth of development work, Psyched Wellness (CSE: PSYC) this morning had a major announcement. The company has seen the Amanita Muscaria mushroom added to the Natural Health Products Ingredients Database of Canada. The approval follows the submission by Psyched for the approval of the mushroom for use as an approved …

Briefing Bright Minds Biosciences News Psychedelics

Bright Minds Biosciences Advances Lead Serotonergic Drug Candidate To Toxicology Studies, Targets Human Trials In 2022

Bright Minds Biosciences (CSE: DRUG) shared today scientific updates regarding its serotonergic drug pipeline. This includes the announcement of advancing the company’s proprietary agonist BMB-101 to the investigational new drug stage enabling safety and toxicology studies for its potential treatment of Dravet syndrome. The biotech firm is selecting BMB-101 as the lead drug candidate in …

Analyst Estimate Briefing Bright Minds Biosciences News Psychedelics

Bright Minds: Eight Capital Assigns $11.50 Price Target To Firm

Last week, Eight Capital launched coverage on a basket of psychedelic companies. This comes after they produced an industry primer during the summer months. The last company to be initiated on is Bright Minds Biosciences (CSE: DRUG), with an C$11.50 price target, or a 67% upside and a buy rating. Eight Capital headlines the note, …

Briefing Creso Pharma News Psychedelics Red Light Holland

Red Light Holland, Creso Pharma Walk From Merger Due To COVID Headwinds

Red Light Holland (CSE: TRIP) and Creso Pharma (ASX: CPH) evidently have elected to walk from their previously announced merger arrangement. The termination is being blamed largely on the impacts of the ongoing COVID-19 pandemic. “Unfortunately, the geographic span of our respective businesses made a merger at this time impractical,” commented Creso’s Chairman Alex Blumenthal. …

Briefing Bright Minds Biosciences News Psychedelics

Bright Minds Biosciences Proprietary Compound Shows Reduction Of Seizures In Pre-Clinical Studies

Bright Minds Biosciences (CSE: DRUG) this morning announced preliminary results from an ongoing study being conducted by the firm. The company has seen efficacy in rodent models of Dravet Syndrome, a form of epilepsy, within ongoing late pre-clinical trials. The efficacy was seen in what the company refers to as its 5-HT2C agonist, BMB-101. The …

Briefing News Psilocybin Psychedelics Revive Therapeutics

Revive Therapeutics Provides Update On Current Psilocybin Programs

Revive Therapeutics (CSE: RVV) this morning provided a corporate update as it pertains to its psychedelic assets. The update primarily focused on the current status of the firms various psychedelics-related development and clinical programs, which largely surround the use of psilocybin. The company currently has a number of ongoing studies as they relate to the …